Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.
Deng Y, Diepstraten ST, Potts MA, Giner G, Trezise S, Ng AP, Healey G, Kane SR, Cooray A, Behrens K, Heidersbach A, Kueh AJ, Pal M, Wilcox S, Tai L, Alexander WS, Visvader JE, Nutt SL, Strasser A, Haley B, Zhao Q, Kelly GL, Herold MJ. Deng Y, et al. Among authors: diepstraten st. Nat Commun. 2022 Aug 12;13(1):4739. doi: 10.1038/s41467-022-32485-9. Nat Commun. 2022. PMID: 35961968 Free PMC article.
Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development.
Aubrey BJ, Janic A, Chen Y, Chang C, Lieschke EC, Diepstraten ST, Kueh AJ, Bernardini JP, Dewson G, O'Reilly LA, Whitehead L, Voss AK, Smyth GK, Strasser A, Kelly GL. Aubrey BJ, et al. Among authors: diepstraten st. Genes Dev. 2018 Nov 1;32(21-22):1420-1429. doi: 10.1101/gad.314286.118. Epub 2018 Oct 26. Genes Dev. 2018. PMID: 30366906 Free PMC article.
Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A, Peddigari S, Mercer CA, Iannizzotto F, Rodriguez ML, Garcia-Cajide M, Amador V, Diepstraten ST, Kelly GL, Salazar R, Kozma SC, Kusnadi EP, Kang J, Gentilella A, Pearson RB, Thomas G, Pelletier J. Domostegui A, et al. Among authors: diepstraten st. Blood. 2021 Jun 17;137(24):3351-3364. doi: 10.1182/blood.2020007452. Blood. 2021. PMID: 33512431 Free PMC article.
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH. Thijssen R, et al. Among authors: diepstraten st. Blood. 2021 May 20;137(20):2721-2735. doi: 10.1182/blood.2020010167. Blood. 2021. PMID: 33824975 Free PMC article.
Loss of TRP53 reduces but does not overcome dependency of lymphoma cells on MCL-1.
Aubrey BJ, Brennan MS, Diepstraten ST, Wang Z, Chang C, Herold MJ, Strasser A, Kelly GL. Aubrey BJ, et al. Among authors: diepstraten st. Cell Death Differ. 2022 May;29(5):1074-1076. doi: 10.1038/s41418-022-00946-9. Epub 2022 Jan 28. Cell Death Differ. 2022. PMID: 35091693 Free PMC article. No abstract available.
Author Correction: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.
Deng Y, Diepstraten ST, Potts MA, Giner G, Trezise S, Ng AP, Healey G, Kane SR, Cooray A, Behrens K, Heidersbach A, Kueh AJ, Pal M, Wilcox S, Tai L, Alexander WS, Visvader JE, Nutt SL, Strasser A, Haley B, Zhao Q, Kelly GL, Herold MJ. Deng Y, et al. Among authors: diepstraten st. Nat Commun. 2022 Aug 25;13(1):5007. doi: 10.1038/s41467-022-32817-9. Nat Commun. 2022. PMID: 36008403 Free PMC article. No abstract available.
22 results